États-Unis - anglais - NLM (National Library of Medicine)

micro labs limited - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate tablets usp are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets usp are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should n

États-Unis - anglais - NLM (National Library of Medicine)

bryant ranch prepack - trimethobenzamide hydrochloride (unii: wdq5p1sx7q) (trimethobenzamide - unii:w2x096qy97) - trimethobenzamide hydrochloride capsules are indicated in adults for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. limitation of use: trimethobenzamide hydrochloride capsules are not recommended for use in pediatric patients due to the risk of extrapyramidal signs and symptoms and other serious central nervous system (cns) effects, and the risk of exacerbation of the underlying disease in pediatric patients with reye’s syndrome or other hepatic impairment. trimethobenzamide hydrochloride capsules are contraindicated in patients with known hypersensitivity to trimethobenzamide [see adverse reactions (6) ]. risk summary the limited available data with trimethobenzamide in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. no adverse developmental effect was observed in animal reproduction studies with administration of trimethobenzamide hydrochloride during organogenesis in pregnant rats at doses 0.16 a

États-Unis - anglais - NLM (National Library of Medicine)

avpak - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate tablets usp are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets usp are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should not be given to patients taking sulfonamides because some sulfonamides may form an insoluble precipitate with formaldehyde in the urine.

États-Unis - anglais - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should n

États-Unis - anglais - NLM (National Library of Medicine)

american health packaging - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate tablets usp are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets usp are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should n

États-Unis - anglais - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - trimethobenzamide hydrochloride (unii: wdq5p1sx7q) (trimethobenzamide - unii:w2x096qy97) - trimethobenzamide hydrochloride capsules are indicated in adults for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. limitation of use: trimethobenzamide hydrochloride capsules are not recommended for use in pediatric patients due to the risk of extrapyramidal signs and symptoms and other serious central nervous system (cns) effects, and the risk of exacerbation of the underlying disease in pediatric patients with reye’s syndrome or other hepatic impairment. trimethobenzamide hydrochloride capsules are contraindicated in patients with known hypersensitivity to trimethobenzamide [see adverse reactions (6)] . the limited available data with trimethobenzamide in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. no adverse developmental effect was observed in animal reproduction studies with administration of trimethobenzamide hydrochloride during organogenesis in pregnant rats at doses 0.16 and 0.8 times

États-Unis - anglais - NLM (National Library of Medicine)

chartwell rx, llc - trimethobenzamide hydrochloride (unii: wdq5p1sx7q) (trimethobenzamide - unii:w2x096qy97) - trimethobenzamide hydrochloride capsules are indicated in adults for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.  limitation of use: trimethobenzamide hydrochloride capsules are not recommended for use in pediatric patients due to the risk of extrapyramidal signs and symptoms and other serious central nervous system (cns) effects, and the risk of exacerbation of the underlying disease in pediatric patients with reye’s syndrome or other hepatic impairment. trimethobenzamide hydrochloride capsules are contraindicated in patients with known hypersensitivity to trimethobenzamide [see adverse reactions (6)] . risk summary the limited available data with trimethobenzamide in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. no adverse developmental effect was observed in animal reproduction studies with administration of trimethobenzamide hydrochloride during organogenesis in pregnant rats

États-Unis - anglais - NLM (National Library of Medicine)

rebel distributors corp - trimethobenzamide hydrochloride (unii: wdq5p1sx7q) (trimethobenzamide - unii:w2x096qy97) - trimethobenzamide 100 mg in 1 ml - tigan ® is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. the injectable form of tigan ® is contraindicated in pediatric patients and in patients with known hypersensitivity to trimethobenzamide.

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - methenamine hippurate - oral tablet - 1gram

États-Unis - anglais - NLM (National Library of Medicine)

avkare - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 118 mg - uroav-b capsules are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uroav-b capsules are contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).